{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Seiler LK"],"funding":["Deutsche Forschungsgemeinschaft","German Center for Infection Research","start-up project SU02 and the Core Facility Diagnostic Centre of the IFB-Tx","European Regional Development Fund"],"pagination":["308"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8871475"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(2)"],"pubmed_abstract":["Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-me"],"journal":["Diagnostics (Basel, Switzerland)"],"pubmed_title":["An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney Transplantation."],"pmcid":["PMC8871475"],"funding_grant_id":["TTU-IICH07.801","85006385","SFB738-B8","ZF4409702 CR8","3442/7-1","01EO0802"],"pubmed_authors":["Phung NL","Lindner P","Thoms S","Kaufeld J","Mayer G","Nikolin C","Erck C","Falk CS","Siegl J","Haller H","Jonczyk R","Immenschuh S","Blume CA","Feederle R","Seiler LK"],"additional_accession":[]},"is_claimable":false,"name":"An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney Transplantation.","description":"Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-me","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-22T19:05:50.222Z","creation":"2025-04-06T02:39:52.281Z"},"accession":"S-EPMC8871475","cross_references":{"pubmed":["35204399"],"doi":["10.3390/diagnostics12020308"]}}